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BRAF Inhibition Generates a Host–Tumor Niche that
Mediates Therapeutic Escape
Inna V. Fedorenko1, Jennifer A. Wargo2, Keith T. Flaherty3, Jane L. Messina4 and Keiran S.M. Smalley1,4
The current study deﬁnes a ﬁbroblast-derived niche that facilitates the therapeutic escape of melanoma cells
from BRAF inhibition. Vemurafenib treatment led to the release of transforming growth factor-β (TGF-β) from the
melanoma cells that increased the differentiation state of the ﬁbroblasts, an affect associated with ﬁbronectin
deposition, increase in α-smooth muscle actin expression, and the release of neuregulin (NRG). At the same time,
vemurafenib directly activated the ﬁbroblasts through paradoxical stimulation of the mitogen-activated protein
kinase pathway, causing them to secrete hepatocyte growth factor (HGF). Treatment with the BRAF/MEK inhibitor
combination reversed the release of HGF. Adhesion of melanoma cells to ﬁbronectin was critical in amplifying
the ﬁbroblast-derived NRG- and HGF-mediated PI3K/AKT (phosphatidylinositol 3'-kinase/AKT) survival signaling
in the melanoma cells following BRAF inhibition. In coculture studies, combination treatment with inhibitors of
BRAF/MET/HER kinase was ineffective at reversing the ﬁbroblast-mediated therapeutic escape from BRAF
inhibition. Instead, it was noted that combined BRAF/PI3K inhibition overcame ﬁbroblast-mediated drug
resistance in vitro and was associated with enhanced antitumor effects in an in vivo xenograft model. Thus, we
show that melanoma cells and ﬁbroblasts remodel their microenvironment in response to BRAF inhibition and
that these adaptations allow tumor cells to evade therapy through increased PI3K/AKT survival signaling.
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INTRODUCTION
Our emerging understanding of therapeutic resistance
suggests a role for both tumor autonomous mechanisms and
adaptive prosurvival signals from the host microenvironment
(Lito et al., 2012; Straussman et al., 2012; Wilson et al., 2012;
Abel et al., 2013). During progression, melanoma cells lose
contact with their natural binding partners, the keratinocytes,
and instead interact with host endothelial cells and ﬁbroblasts
(Hsu et al., 2000; Li et al., 2001). Fibroblasts also contribute to
the escape of melanoma cells from vemurafenib therapy, in
part, through hepatocyte growth factor (HGF) signaling
(Straussman et al., 2012). In addition, tumor-derived growth
factors, such as epithelial growth factor (EGF), neuregulin
(NRG), and IGF-I, affect the responsiveness to BRAF inhibition
and may even drive BRAF inhibitor resistance (Villanueva
et al., 2010; Wilson et al., 2012; Abel et al., 2013). Other
studies have suggested that adhesion to the extracellular
matrix (ECM) protects cancer cells from apoptosis following
treatment with chemotherapeutics. This phenomenon, known
as cell adhesion–mediated drug resistance, was ﬁrst described
for multiple myeloma, with adhesion to ﬁbronectin (FN),
decreasing the sensitivity to melphalan (Damiano et al., 1999;
Hazlehurst et al., 2000; Hazlehurst and Dalton, 2001). The
extent to which melanoma cells and their microenvironment
interact to provide a “protective sanctuary” that allows the
cancer cells to evade therapy is not well understood. In the
present study, we uncovered a previously uncharacterized
ECM-derived protective niche that drives therapeutic escape
through the ampliﬁcation of host-derived survival signals.
Unexpectedly, inhibition of BRAF also led to paradoxical
mitogen-activated protein kinase (MAPK) signaling–mediated
differentiation and ECM deposition in normal skin ﬁbroblasts
(BRAF wild-type), suggesting that off-target effects of kinase
inhibitors remodel the host environment. We propose a role
for bi-directional signaling between the tumor and host in the
adaptive responses to therapy and demonstrate that host cells
are an active player in the escape process. Our data suggest
that future therapeutic strategies will require the targeting of
both the tumor and host responses.
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RESULTS
Plating of green ﬂuorescent protein (GFP)–tagged melanoma
cells onto a conﬂuent ﬁbroblast monolayer conveyed
near-total protection to the growth inhibitory effects of
vemurafenib treatment (3 μM, 72 hours) (Figure 1a). Mechan-
istically, it was found that treatment of the ﬁbroblasts using
transforming growth factor (TGF)-β, conditioned media
(CM+vemu) from melanoma cells treated with vemurafenib
(3 μM, 48 hours), or vemurafenib alone (3 μM, 48 hours)
increased their differentiation, as shown by the increased
expression of FN and α-smooth muscle actin expression
(α-SMA) (Figure 1b and c). Although vemurafenib alone
induced ﬁbroblast differentiation, the extent of this was less
than either CM+vemu or TGF-β alone. The stimulatory
effects of the melanoma CM on the ﬁbroblasts was
TGF-β-dependent, with the addition of the TGF kinase
inhibitor SB505124 found to partially inhibit ﬁbroblast
activation (Supplementary Figure 1 online). The increased
expression of FN was required for ﬁbroblast survival, with its
small interfering RNA (siRNA)–mediated knockdown asso-
ciated with increased ﬁbroblast cell death under serum-free
conditions (Supplementary Figure 2 online).
Previous work from our lab has demonstrated BRAF
inhibitor treatment to induce an epithelial–mesenchymal
transition–like state in melanoma cells, a phenotype often
driven through TGF-β signaling (Fedorenko et al., 2015).
As exogenous TGF-β, vemurafenib, and CM from
vemurafenib-treated melanoma cells induced the differentia-
tion of ﬁbroblasts, we next asked whether BRAF inhibition led
to the release of TGF-β from the melanoma cells. Treatment
with vemurafenib increased the protein expression of TGF-β
in three out of six BRAF-mutant melanoma cell lines
(Figure 2a). Also noted was an increase in mRNA levels, as
well as the release of TGF-β, as measured by quantitative
real-time reverse-transcriptase–PCR (qRT-PCR) and ELISA
assays (Figure 2b and c). The potential clinical relevance of
these ﬁndings was suggested by the analysis of pre- and post-
treatment specimens from melanoma patients on BRAF
inhibitor therapy, with increased post-treatment levels of
TGF-β mRNA observed in two out of four patients analyzed
(Figure 2d). Although the origin of the TGF-β could not be
attributed exclusively to melanoma cells (because of the
nature of patient tissue, in which many cell types interact
intimately), these clinical results are consistent with our
in vitro ﬁndings.
Increased receptor tyrosine kinase (RTK) signaling is known
to mediate the escape of melanoma cells from BRAF
inhibition (Nazarian et al., 2010; Straussman et al., 2012;
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Figure 1. BRAFV600E melanoma cells and vemurafenib (vemu) induce ﬁbroblast differentiation. (a, left) Green ﬂuorescent protein (GFP)–tagged 1205Lu
melanoma cells were plated on either tissue culture plastic or conﬂuent monolayers of unlabeled FF2504 ﬁbroblasts and treated with vemurafenib
(3 μM, 72 hours). (Right) Quantiﬁcation of GFP+ melanoma cells, N=3. (b) FF2447 ﬁbroblasts were treated with either conditioned medium (CM) from 1205Lu
cells, CM from 1205Lu cells treated with vemurafenib, 3 μM for 48 hours (CM+vemu), 12.5 pg ml−1 transforming growth factor (TGF-β1), or vemu before being
stained for ﬁbronectin (FN, yellow) and α-smooth muscle actin (α-SMA, red). Bar=100 μm. (c) Fibroblast differentiation was measured by the level of FN and
α-SMA expression. FN and α-SMA expression was analyzed using Deﬁniens Developer v.2.0 software suite; total ﬂuorescence intensity per nuclei was quantiﬁed.
*P≤ 0.05, **P≤0.01, and ****P≤0.0001.
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Abel et al., 2013). A role for melanoma- and vemurafenib-
activated ﬁbroblasts in the release of prosurvival melanoma
growth factors was demonstrated by ELISA assays in which
TGF-β (0.1 and 1 ngml−1) or vemurafenib (3 μM) treatment
increased the ﬁbroblast-mediated release of NRG and HGF,
respectively (Figure 3a and b). Interestingly, maximal
ﬁbroblast activation seemed to be dependent on dual
TGF-β/vemurafenib treatment, with studies showing that
vemurafenib alone failed to induce NRG release from
ﬁbroblasts, TGF-β1 alone failed to induce HGF release from
ﬁbroblasts, and the observation that TGF-β inhibition did
not fully suppress ﬁbroblast activation (Supplementary
Figure 1 online).
Previous work has shown that BRAF inhibition activates
MAPK signaling in systems with either Ras mutations or
upstream RTK signaling, as a result of CRAF transactivation
(Hatzivassiliou et al., 2010; Poulikakos et al., 2010). To date,
the ability of BRAF inhibitors to activate extracellular signal–
regulated kinase (ERK) signaling in normal, primary cells has
not been reported. We next determined the requirement for
paradoxical ERK activation in the vemurafenib-mediated
release of ﬁbroblast HGF. Western blot analyses showed
single-agent vemurafenib to induce paradoxical MAPK
signaling in primary human skin ﬁbroblasts and that this
was reversed through combination with the MEK inhibitor
trametinib (Figure 3c). A role for paradoxical ERK activation
in ﬁbroblast-mediated melanoma therapeutic escape was
demonstrated in ELISA assays that showed the combination of
trametinib with vemurafenib to completely suppress the
vemurafenib-mediated increase in HGF expression
(Figure 3d).
Adhesion to ECM proteins, such as FN, can increase
cell survival by amplifying RTK signals. To determine the
role of FN expression in amplifying ﬁbroblast-derived growth
signals, we identiﬁed three melanoma cell lines whose FN
expression increased following vemurafenib treatment
(Supplementary Figure 4 online). Knockdown of FN using
siRNA limited EGFR, c-MET, and ERBB3 receptor phosphor-
ylation following ligand challenge, an effect associated with
impaired PI3K/AKT (phosphatidylinositol 3'-kinase/AKT)
signaling (Figure 4a and b).
An immunohistochemical analysis of specimens from
melanoma patients treated with vemurafenib (n= 9) was then
performed to validate that melanoma cells and ﬁbroblasts
coexist in close proximity, and that FN expression was
increased at these sites of interaction. Examination by two
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Figure 2. Vemurafenib induces the release and secretion of transforming growth factor-β (TGF-β) from some BRAF-mutant melanoma cells. (a) Western blot
analysis of six melanoma cell lines treated with vemurafenib (3 μM, 72 hours). Densitometry for TGF-β is depicted in fold changes compared with each respective
control. Bar=50 μm. (b) Quantitative real-time reverse-transcriptase–PCR (qRT-PCR) for TGF-β1 shows vemurafenib-mediated induction of TGF-β1 mRNA
expression in 1205Lu. Data were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 18S endogenous controls. (c) ELISA showing
induction of TGF-β release from BRAFV600E melanoma cell lines following 3 μM vemurafenib treatment (72 hours), expressed in pg ml−1. (d) Data show qRT-PCR
experiments measuring the levels of TGF-β1 mRNA in four matched (before and after treatment) pairs of melanoma patient specimens receiving vemurafenib
therapy (960 mg twice daily); error bars represent technical replicates of a single RNA extraction.
IV Fedorenko et al.
Host-Mediated Resistance in Melanoma
www.jidonline.org 3117
independent pathologists conﬁrmed areas in the
post-treatment specimens with high levels of FN staining,
with inﬁltrating spindle-like cells, characteristic of ﬁbroblasts,
noted in 3/9 samples (Figure 4c). Areas of strong FN staining
were also seen at the tumor–stroma interface, at the sites of
melanoma cells and ﬁbroblast interaction (Figure 4c).
Our studies thus far demonstrated that activated ﬁbroblasts
increased the co-operative effects of RTKs and FN upon PI3K
signaling in melanoma cells. We next asked whether
inhibition of PI3K/AKT signaling was sufﬁcient to reverse the
protection conferred by the ﬁbroblasts to the melanoma cells.
Quantiﬁcation of pAKT staining in GFP–tagged WM9
melanoma cells revealed higher basal signaling levels
following plating upon ﬁbroblasts compared with
plastic (Figure 5a). Upon treatment with vemurafenib
(3 μM, 24 hours), signiﬁcant increases in pAKT staining were
observed in the melanoma cells following adhesion to three
independent ﬁbroblast cell lines (Figure 5a and b).
Vemurafenib was not noted to induce AKT signaling in the
ﬁbroblasts (Supplementary Figure 5 online). In line with the
observation that FN ampliﬁes AKT signaling through multiple
RTKs (Figure 4a and b), only limited inhibition of AKT
signaling was seen when the cocultures were treated with the
combination of crizotinib and lapatinib with vemurafenib
(Figure 5c and d). As expected, the inhibitory effects of the
RTK inhibitors were stronger when the melanoma cells were
plated on ﬁbroblasts as opposed to on plastic; however, these
effects were still quite limited (Figure 5c and d). Interestingly,
although the combination of the BRAF inhibitor with lapatinib
and crizotinib induced a relatively small decrease in cell
proliferation, this triple combination was ineffective at
inducing apoptosis, as measured by poly (ADP-ribose)
polymerase (PARP) cleavage—a possible reﬂection of the
incomplete inhibition of PI3K/AKT signaling (Supplementary
Figure 6 online and Figure 5c and d). The combination of
vemurafenib with the PI3K inhibitor GDC-0941 was asso-
ciated with a near-complete inhibition of the ﬁbroblast-
mediated AKT signaling in the melanoma cells, an effect
associated with a marked increase in PARP cleavage (Figure
5c and d). Evidence for the role of PI3K in facilitating
ﬁbroblast-mediated therapeutic escape was demonstrated by
the ability of the BRAF+PI3K inhibitor combination to
enhance vemurafenib-mediated apoptosis in two additional
melanoma cells lines, each plated on three individual primary
human skin ﬁbroblast cultures (Figure 6a). The extent of
apoptosis induction following BRAF+PI3K inhibitor treatment
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Figure 3. Vemurafenib and transforming growth factor-β (TGF-β) co-operate to release growth factors from primary human ﬁbroblasts. (a) ELISA data showing
neuregulin (NRG) release from three human skin ﬁbroblast cell lines, following treatment with TGF-β (100 pgml−1 and 1 ngml−1) for 72 hours. (b) ELISA data
showing hepatocyte growth factor (HGF) release from three human skin ﬁbroblast cell lines, following treatment with vemurafenib (3 μM, 72 hours). (c) Western
blot analysis showing vemurafenib (3 μM) to induce paradoxical mitogen-activated protein kinase (MAPK) signaling in primary human skin ﬁbroblasts that could
be blocked through combination with trametinib (10 nM). (d) ELISA data showing HGF release from two human skin ﬁbroblast cell lines, following 72-hour
treatment with 3 μM vemurafenib, 10 nM trametinib, or the combination. *P≤0.05, **P≤ 0.01, ***P≤ 0.001, and ****P≤0.0001.
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was slightly increased on ﬁbroblasts compared with plastic in
the WM793 cell line but not the 1205Lu (Supplementary
Figure 7 online). The in vivo relevance of microenvironment-
mediated PI3K/AKT signaling in the escape response of
melanoma cells was demonstrated in a human melanoma
mouse xenograft model, in which dosing with the combina-
tion of the BRAF inhibitor PLX4720 and the PI3K inhibitor
GDC-0941 caused signiﬁcant levels of tumor regression
compared with either PLX4720 or GDC-0941 alone
(Figure 6b). A model showing the proposed interaction of
the host–melanoma cells under vemurafenib treatment is
shown in Figure 6c.
DISCUSSION
Although there is some evidence that host ﬁbroblasts
also mediate resistance to BRAF inhibition through increased
HGF release, the mechanisms underlying the melanoma
cell/ﬁbroblast interaction remain poorly described
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Figure 4. Adhesion to ﬁbronectin (FN) ampliﬁes receptor tyrosine kinase (RTK) signals in BRAFV600E mutant melanoma cells. (a) The 1205Lu cells were treated
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(Straussman et al., 2012). Fibroblast survival is dependent on
attachment to an appropriate ECM, with adhesion to
FN constituting a major survival signal (Zhang et al., 1995;
Ilic et al., 1998; Almeida et al., 2000; Lin et al., 2011). FN is
also a potent chemoattractant for ﬁbroblasts that stimulates
their motility (Postlethwaite et al., 1981). Our data suggest that
the release of TGF-β from melanoma cells treated with a BRAF
inhibitor and the effects of the BRAF inhibitor itself have
critical roles in the activation of host ﬁbroblasts. Treatment
with TGF-β, vemurafenib, or CM from vemurafenib-treated
melanoma cells increased ﬁbroblast differentiation. At the
same time, either exogenous TGF-β or vemurafenib enhanced
NRG and HGF release from ﬁbroblasts, respectively. Recent
reports have suggested that TGF-β released from melanoma
cells upon BRAF inhibition may also increase RTK expression
in melanoma cells (Sun et al., 2014). This, along with the data
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Figure 5. Fibroblasts protect melanoma cells from vemurafenib (vemu)-mediated cytotoxicity through phosphatidylinositol 3'-kinase/AKT (PI3K/AKT). (a)
Green ﬂuorescent protein (GFP)–tagged WM9 melanoma cells were plated on plastic or ﬁbroblast monolayers and treated with 3 μM vemurafenib (24 hours)
before being stained for pAKT (Ser473). Bar=50 μm. (b) Fold changes in vemurafenib-induced pAKT from a were calculated. (c) Melanoma cells treated with a
single agent or with combinations of 3 μM vemurafenib (BRAFi), 3 μM GDC-0941 (PI3Ki), 200 nM crizotinib (METi), and 1 μM lapatinib (HER2i). Analysis of pAKT
(Ser473) and cleaved poly (ADP-ribose) polymerase (PARP) on individual GFP–tagged cells was performed using ﬂow cytometry. Histograms show levels of
pAKT, with an AKT+ gate drawn based on 3 μM GDC-0941 treatment on plastic. (d) Column graphs show the percentage of melanoma cells from c that are in the
AKT+ and cleaved PARP+ populations. **P≤0.01 and ***P≤0.001.
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contained herein, suggests TGF-β release to set the stage for
complex growth factor–mediated cross-talk between
melanoma cells and ﬁbroblasts. Analysis of tumor
specimens from melanoma patients on BRAF inhibitor
therapy suggest that melanoma cells and ﬁbroblasts exist in
close proximity in vivo, suggesting the likelihood of this
cross-talk occurring.
The ability of vemurafenib to stimulate HGF release from
normal primary skin ﬁbroblasts was unexpected, and it was
linked to the ability of vemurafenib to induce paradoxical
MAPK signaling in normal human ﬁbroblasts. Paradoxical
MAPK signaling occurs when BRAF inhibitors transactivate
CRAF as result of upstream signals emanating from either Ras
mutations or increased levels of growth factor signaling
(Hatzivassiliou et al., 2010; Joseph et al., 2010; Poulikakos
et al., 2010; Gibney et al., 2013). Although the BRAF/MEK
inhibitor combination was noted to suppress the release of
HGF from the ﬁbroblasts, this would not be expected to fully
reverse host-mediated resistance. Other signals, such as
melanoma-derived TGF-β, would still be able to activate the
host ﬁbroblasts, perhaps partly explaining why the dabrafe-
nib/trametinib combination can delay but not prevent
the onset of acquired resistance in melanoma patients
(Flaherty et al., 2012; Larkin et al., 2014). Although TGF-β
released locally from the BRAF inhibitor–treated melanoma
cells appeared to constitute an important mechanism of
ﬁbroblast activation, it is worth noting that melanoma cells
release other factors known to stimulate ﬁbroblasts, including
platelet-derived growth factor and stromal-derived factor
(Orimo et al., 2005; Willenberg et al., 2012; Whipple and
Brinckerhoff, 2014). There is also evidence that the
introduction of mutant BRAF into melanoma cells increases
their secretion of IL-1α that causes tumor-associated
ﬁbroblasts to induce immune suppression (Khalili et al.,
2012).
The observation that drug-treated melanoma cells activated
ﬁbroblasts, increasing NRG and HGF release, was suggestive
of a role for host cells in mediating therapeutic escape. Under
baseline conditions, BRAF-mutant melanoma cells exhibit
high levels of feedback inhibition in the MAPK signaling
pathway that suppresses the ability of RTKs to activate ERK
(Lito et al., 2012). Following vemurafenib treatment,
the feedback inhibition of the MAPK pathway becomes
deregulated, increasing the responsiveness to growth factors
such as EGF, NRG, HGF, and ﬁbroblast growth factor
(Lito et al., 2012). There is already evidence that both HGF
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Figure 6. Combined BRAF/phosphatidylinositol 3'-kinase (BRAF/PI3K) inhibition reverses ﬁbroblast-mediated drug resistance and leads to tumor regression
in vivo. (a) Green ﬂuorescent protein (GFP)–tagged melanoma cells (WM793, 1205Lu) were seeded on top of ﬁbroblast cell lines (FF2504, FF2507, FF2447)
overnight before being treated with either vehicle control or 3 μM vemurafenib (vemu) and 3 μM GDC-0941 for 72 hours before being stained for Annexin-V and
analyzed by ﬂow cytometry. P-values were calculated between vemurafenib only and vemurafenib/GDC-0941 combination treatments. (b) Xenograft tumor
volume was calculated using the modiﬁed ellipsoid formula (tumor volume = ½× L×W2). P-values were calculated between control and treatment groups. (c)
Model showing the interaction of the host–melanoma cells under vemurafenib treatment. *P≤0.05, **P≤0.01, and ***P≤0.001.
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and NRG limit responses to vemurafenib and its analog
PLX4720 (Sharma et al., 2010; Straussman et al., 2012; Abel
et al., 2013). For all growth factors evaluated, the expression
of FN was required for the maximal activation of PI3K/AKT
signaling, suggesting a critical role for environmental
remodeling in the ampliﬁcation of these escape signals. In
this instance, the FN seemed to be derived from the activated
ﬁbroblasts and from the melanoma cells themselves. It is
already known in lung cancer that co-operation between
integrin and RTK signaling is required for the optimal
activation of the downstream PI3K/AKT pathway (Morello
et al., 2011). Similar ﬁndings have also been reported for
α5β1-integrin, in which a functional association between the
integrin with the VEGFR3 receptor in lymphatic vessels and
EGFR and ERBB3 in intestinal epithelial cells is required for
efﬁcient signaling (Lee and Juliano, 2002; Zhang et al., 2005).
In some experimental systems, integrin α5β1 also complexes
with c-MET, with the presence of either vitronectin or FN
found to signiﬁcantly increase the level of MET receptor
phosphorylation (Rahman et al., 2005).
When cocultured with ﬁbroblasts, vemurafenib markedly
enhanced increased AKT signaling in the melanoma cells.
The activation of AKT was mediated through multiple RTKs
and by direct melanoma/ﬁbroblast adhesion, with the BRAF/
PI3K inhibitor combination found to be signiﬁcantly more
effective at reversing the adaptive survival compared with a
BRAF inhibitor combined with multiple RTK inhibitors. It was
also found that combined BRAF/PI3K inhibition was signiﬁ-
cantly more effective at reducing the growth of melanoma
xenografts compared with either BRAF or PI3K inhibitor
alone. These data are in agreement with recent preclinical
studies demonstrating that the combination of a BRAF and
PI3K inhibitor induces a more rapid regression of tumors in
BRAF V600E/PTEN-null GEMMs compared with BRAF
inhibitor alone (Marsh Durban et al., 2013). In our xenograft
model, PLX4720 was relatively weak as a single agent. This is
likely a consequence of the 1205Lu melanoma cell line being
both BRAF mutant and null for PTEN. There is already
evidence from our lab and others that PTEN loss can be a
mediator of intrinsic BRAF inhibitor resistance, and there is
evidence that aberrant PTEN function is associated with a
shorter PFS in melanoma patients receiving BRAF inhibitor
therapy (Paraiso et al., 2011; Xing et al., 2011; Nathanson
et al., 2013). The observed heterogeneity in TGF-β secretion
(highest in PTEN-null cell lines) supports these ﬁndings.
The requirement for PI3K signaling in microenvironment-
mediated therapeutic escape was demonstrated by the ability
of combined BRAF/PI3K inhibition to overcome this
protection. Taken together, these data suggest that the PI3K/
AKT signaling pathway integrates multiple host-derived
signals required for therapeutic adaption. This idea is also
supported by recent work suggesting that mutations in AKT1
are involved in tumor-intrinsic therapeutic adaptation
(Shi et al., 2014). Loss of PTEN expression and/or function
on BRAF inhibitor therapy has been suggested as a
mechanism of therapeutic escape (Van Allen et al., 2014).
Although previous studies showed variable cytokine
production in established ﬁbroblast lines, the current study
used early-passage primary cultures from three healthy
human donors and is likely to better represent ﬁbroblast
biology. A more extensive characterization of clinical samples
may improve our understanding of the cytokines produced by
the stroma in patients treated with BRAF inhibitors
(Khalili et al., 2012; Straussman et al., 2012).
Our current understanding of BRAF inhibitor escape
suggests a role for short-term adaptation in which cells evade
the immediate effects of the drug. The data contained herein
suggest a role for host–tumor cross-talk in the earliest phases
of adaptation; however, it is also likely that pressure from
the host may also help to select for escaping clones or
mutations. Long-term treatment of melanoma patients with
small-molecule inhibitors such as dabrafenib and vemurafe-
nib will depend on their ability to suppress the escaping
population of cells that ultimately repopulate the tumor. This
study presents evidence that adaptive changes in normal host
cells facilitate the escape of melanoma cells from BRAF
inhibition. It is likely that combination therapies such as BRAF
+PI3K inhibition may be one strategy to limit the protection
conveyed by the host.
MATERIALS AND METHODS
Cell culture and reagents
The 1205Lu, WM9, WM793, WM164, WM983A, and 451Lu
melanoma cells lines and FF2504, FF2507, and FF2447 human
primary skin ﬁbroblasts were a gift from Dr Meenhard Herlyn
(The Wistar Institute, Philadelphia, PA). WM9-GFP was from Dr Peter
Forsyth (Mofﬁtt Cancer Center, Tampa, FL). The identities of all cell
lines were conﬁrmed by Biosynthesis (Lewisville, TX) through STR
validation analysis. Cell lines were maintained in 5% fetal bovine
serum/RPMI-1640. Conditioned medium was prepared by adding
fresh medium to 1205Lu cells for 48 hours in the presence of vehicle
or 3 μM vemurafenib. Then, the medium was collected and diluted
1:1 with fresh medium, matching the concentrations of drugs/vehicle.
SB505124 was obtained from Selleck Chemicals (Houston, TX).
Western blotting
Proteins were extracted and western blotting was performed as
described previously (Fedorenko et al., 2015). Uniform protein
loading was conﬁrmed by blotting for glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). The antibodies to pAKT S473, total AKT,
pERK, total ERK, pMet (Tyr1234/1235), pEGFR (Y1172),
pHER3 (Y1289), and TGF-β were from Cell Signaling Technology
(Beverly, MA). The α-SMA antibodies were from Abcam (Cambridge,
MA), whereas the antibody against FN antibody was from BD
(San Jose, CA), GAPDH was from Sigma (St Louis, MO), and
phalloidin was from Invitrogen (Life Technologies, Carlsbad, CA).
Immunoﬂuorescence staining
Melanoma and primary skin ﬁbroblast cells were plated on glass
coverslips overnight before treatment. Cells were then ﬁxed, stained,
and imaged as described previously (Fedorenko et al., 2015). Images
were analyzed using the Deﬁniens Developer v.2.0 (Deﬁniens AG,
Munich, Germany) software suite. The total ﬂuorescence intensity
was normalized to the number of nuclei (stained by DAPI
(4',6-diamidino-2-phenylindole)) for monocultures or to the number
of GFP–positive cells in cocultures. For coculture experiments,
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melanoma cells were GFP–labeled, plated on unlabeled ﬁbroblasts,
and imaged using ﬂuorescence microscopy. Melanoma and
ﬁbroblast cells were differentiated by the GFP label. In rescue
experiments, the number of GFP+ cells were counted for three
5× ﬁeld of view images per treatment (N= 3). Fibroblast
differentiation was measured by the level of FN and α-SMA
expression.
RNA interference
Cells were plated and left to grow overnight. The 5% fetal bovine
serum/RPMI medium was replaced with Opti-MEM (Invitrogen).
FN pool siRNAs in complex with Lipofectamine 2000 (Invitrogen)
were added. Scrambled, nontargeting siRNAs were used as controls.
Cells were transfected for 24–72 hours before treatment.
ELISA assays
The TGF-β1 and HGF ELISA Kits were purchased from R&D Systems
(Minneapolis, MN). The NRG ELISA Kit was from Abcam
(Cambridge, MA).
qRT-PCR for cell lines and patient specimens
Cells were treated for 72 hours, and then total RNA was isolated
using Qiagen’s RNeasy Mini Kit (Hilden, Germany). cDNA from a
cohort of patient specimens was generously shared by Keith
Flaherty from Massachussetts General Hospital. Patient specimens
were obtained with written, informed patient consent according to
approved protocols by the Institutional Review Board at the
Massachussetts General Hospital. The pretreatment biopsies were
performed between 0 and 30 days before initiating therapy, and
on-treatment biopsies were collected between 7 and 24 days after
the initiation of therapy. The following TaqMan Gene Expression
Assays primer/probes were used: Hs00365052_m1 (FN),
P/N 4319413E (18S), and Hs99999905_m1 (GAPDH). The 18S
and GAPDH data were used to normalize TGF-β1, accounting for
cellularity. qRT-PCR reactions were performed as described
previously (Paraiso et al., 2011).
Flow cytometry
Cells were grown overnight, and then treated with vehicle (DMSO),
3 μM vemurafenib, 3 μM GDC-0941, or the two drugs in combination
(72 hours). Cells were stained for Annexin-V and TMRM
(tetramethylrhodamine methyl ester), as described previously
(Fedorenko et al., 2015).
For analysis of pAKT and cleaved PARP, FF2504 human primary
skin ﬁbroblasts (3.0×105 cells) were plated in 6-well plates
overnight. GFP–tagged WM9 melanoma cells (3.0× 105 cells) were
then plated either on plastic or on FF2504 ﬁbroblasts and incubated
overnight. Cells were then treated with 3 μM vemurafenib (BRAFi),
3 μM GDC-0941 (PI3Ki), 200 nM crizotinib (METi), and/or 1 μM
lapatinib (HER2i) for 24 hours before being collected by scraping,
ﬁxed with 4% paraformaldehyde (10minutes, room temperature),
and permeabilized with 100% cold methanol (1 hour, room
temperature). Cells were stained with pAKT conjugated to AlexaFluor
647 (Ser473; Cell Signaling Technology, Beverly, MA) and cleaved
PARP conjugated to phycoerythrin (BD) in 0.5% bovine serum
albumin in phosphate-buffered saline (1 hour, room temperature).
Cells were analyzed by ﬂow cytometry.
Animal studies
All animal studies were carried out under approved protocols by the
Institutional Animal Care and Use Committee at the University of
South Florida. Female SHO mice (Charles River) were subcuta-
neously injected with 2.5× 106 cells per mouse. Tumors were
allowed to grow to ~ 100mm3. Mice were administered D10001
control chow, AIN-76A 417mg kg−1 PLX4720-formulated chow
(Research Diets, New Brunswick, NJ), vehicle (0.5% methylcellulose,
0.2% Tween-80) oral gavage, or GDC-0941 oral gavage
(150mg kg− 1) daily for 8 days. Mouse tumor volumes (1×2× L×W2)
were measured.
Statistical analysis
Results are reported as mean values, error bars indicating ± SEM.
GraphPad Prism 6 software was used to calculate statistical
signiﬁcance of magnitude of changes between different conditions
using the parametric unpaired t-test with P-values depicted as
follows: *P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001, and ****P⩽ 0.0001.
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